Answer
Selumetinib blocks the RAF-MEK-ERK signalling pathway by inhibiting MEK1/2, which can inhibit proliferation and survival of tumour cells in which this pathway is activated.
Sources for this answer
- Koselugo 5 mg granules in capsule for openingAstraZeneca UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 1Document updated
Sources checked